Checkpoint inhibitor-based immunotherapy targeting the programmed cell death 1 (PD-1) pathway has acquired a leading role in the management of recurrent or metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) [24]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.